Image may be NSFW.
Clik here to view.
Image may be NSFW.
Clik here to view.
| Patent No | Expiry Date | |
|---|---|---|
| 5698226*PED | Jul 29, 2012 |
Lamotrigine /ləˈmoʊtrɨˌdʒiːn/, marketed in most of the world as Lamictal /ləˈmɪktəl/ by GlaxoSmithKline, is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder. It is also used off-label as an adjunct in treating clinical depression.[1] For epilepsy, it is used to treat focal seizures, primary and secondary tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome.
Like many other anticonvulsant medications, lamotrigine also seems to act as an effective mood stabilizer, and has been the first US Food and Drug Administration (FDA)-approved drug for this purpose since lithium, a drug approved almost 30 years earlier.
It is approved for the maintenance treatment of bipolar type I. Chemically unrelated to other anticonvulsants (due to lamotrigine being a phenyltriazine), lamotrigine has many possible side-effects.
Lamotrigine is generally accepted to be a member of the sodium channel blocking class of antiepileptic drugs,[2] but it could have additional actions since it has a broader spectrum of action than other sodium channel antiepileptic drugs such as phenytoin and carbamazepine and is effective in the treatment of the depressed phase of bipolar disorder, where as other sodium channel blocking antiepileptic drugs are not.
In addition, lamotrigine shares few side-effects with other, unrelated anticonvulsants known to inhibit sodium channels, which further emphasises its unique properties.[3] Lamotrigine is inactivated by hepatic glucuronidation.[4]
Ламотрижин (Lamotrigine)
UV – range
| Image may be NSFW. Clik here to view.  |
||||
| Conditions : Concentration – 1 mg / 100 ml | ||||
| The solvent designation graphics | Methanol Image may be NSFW. Clik here to view.  |
Water Image may be NSFW. Clik here to view.  |
0.1М HCl Image may be NSFW. Clik here to view.  |
0.1M NaOH Image may be NSFW. Clik here to view.  |
|---|---|---|---|---|
| Maximum absorption | Observed decay |
Observed decay |
267 nm | 307 nm |
| Image may be NSFW. Clik here to view.  |
- | - | 277 | 285 |
| e | - | - | 7100 | 7300 |
IR – spectrum
| Wavelength (μm) |
|---|
| Image may be NSFW. Clik here to view.  |
| Wave number (cm -1 ) |
Reference
-
UV and IR Spectra. H.-W. Dibbern, R.M. Muller, E. Wirbitzki, 2002 ECV
-
NIST / EPA / NIH Mass Spectral Library 2008
-
Handbook of Organic Compounds. NIR, IR, Raman, and UV-Vis Spectra Featuring Polymers and Surfactants, Jr., Jerry Workman. Academic Press, 2000.
-
Handbook of ultraviolet and visible absorption spectra of organic compounds, K. Hirayama. Plenum Press Data Division, 1967.
Brief background information
| Salt | ATC | Formula | MM | CAS |
|---|---|---|---|---|
| - | N03AX09 | C9H7Cl2N5 | 256.10 g / mol | 84057-84-1 |
Application
-
anticonvulsant
-
ingibitor glutamat
-
Lamotrigine is the common name for 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine which is a commercially marketed, pharmaceutically active substance known to be useful for the treatment of epilepsy and bipolar disorder. Lamotrigine (Formula I. below) has an empirical formula of C9H7N5Cl2 and a molecular weight of 256.09.
-
Lamotrigine is currently available in its anhydrous crystalline form which is characterized by the X-ray Powder Diffraction (XRD) spectrum shown in Figure 2.
-
Lamotrigine and its pharmaceutically acceptable acid addition salts are generally described in U.S. Patent No. 4,560,687 (“the ‘687 patent”). The ‘687 patent, however, provides no examples for preparing lamotrigine.
-
U.S. Patent No. 4,602,017 (“the `017 patent”) discloses a process for preparing lamotrigine by cyclizing the intermediate 2-(2,3-dichlorophenyl)-2-guanidinylimino acetonitrile (Formula VI, below) by refluxing it in an alkanol in the presence of a strong base. The product is then treated with ice water, stirred for 30 minutes, filtered, and recrystallized to produce a residue, which is treated with isopropanol to yield lamotrigine. The process described in the ‘017 patent for preparing lamotrigine is illustrated in Scheme 1.
-
Various references disclose other different processes for producing lamotrigine. For example, WO 00/35888 discloses a process for preparing the intermediate of Formula IV, and describes preparing lamotrigine using this intermediate by a process similar to the one shown in Scheme 1 but using, in the last step, an aqueous solution of potassium hydroxide instead of the methanolic solution.
-
U.S. Patent No. 5,912,345 discloses cyclizing the intermediate of Formula VI using ultraviolet or visible radiation and heating to reflux temperature.
-
WO 01/49669 discloses the reaction of intermediates of Formula IV and Formula V to give intermediate Formula VI using sulfuric acid and p-toluenesulfonic acid. Cyclization is then performed by refluxing in an aliphatic alkanol in the presence of a base. The obtained lamotrigine is then purified by recrystallization or chromatographic separation to produce lamotrigine with a purity of 99.70 (calculated by HPLC).
-
U.S. Patent No. 5,925,755 discloses preparing lamotrigine from 6-(2,3-dichlorophenyl)-5-chloro-3-thiomethyl-1,2,4-triazine that has been dissolved in ethanol saturated with ammonia gas, by heating in a sealed glass tube in an autoclave at 180° C/1930 kPa for 72 hours followed by recrystallizing from methanol.
-
Lamotrigine is known to form solvates with different alcohols. For example, according to an article published in 1989 by Robert W. Janes et al- in Acta Cryst. (1989), C45, 129-132, entitled “Structure of Lamotrigine Methanol Solvate: 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine-Methanol, A Novel Anticonvulsant Drug,” the crystal structure of a sample of “lamotrigine methanol solvate” was provided by the Wellcome Research Laboratories, UK, and a second form of lamotrigine was crystallized from absolute ethanol. According toEP 0 800 520 B 1, published on October 15, 1997, “lamotrigine ethanolate” can be obtained by crystallization of lamotrigine from ethanol (see Examples 5 and 6). Similarly, EP 0 021 121 teaches that “lamotrigine isoproponate” can be obtained by recrystallization from isopropanol (see Example 1). Lamotrigine alcohol solvates can be dried to yield anhydrous lamotrigine. For example, WO 96/20935 describes the drying and recystallization from methanol of anhydrous lamotrigine having a meriting point of 218° C (see Example 6).
-
Most of the known processes for preparing lamotrigine do so only in low yields and by using drastic conditions (e.g., temperature and pressure) or by using dangerous reagents or expensive equipment. Moreover, the known processes only describe preparing lamotrigine as a crude product that is then purified by recrystallization from a solvent and fail to disclose any other processes for purifying lamotrigine.
Synthesis pathway
Trade names
| Country | Trade name | Manufacturer |
|---|---|---|
| Germany | Elmendos | GlaxoSmithKline |
| Lamictal | -»- | |
| various generic drugs | ||
| France | Lamikstart | GlaxoSmithKline |
| Lamictal | Novartis | |
| UK | -»- | GlaxoSmithKline |
| Italy | -»- | -»- |
| United States | -»- | -»- |
| Ukraine | Lamictal | GlaxoSmithKline Pharmaceuticals SA, Poland |
| Herolamyk | Gerota Farmatseutika GmbH (manufacturer responsible for batch release), Austria Deksel Ltd., Israel |
|
| Lamotrin | OOO «Pharma Home» Ukraine | |
| Lamitrin | Farmasayns Inc., Canada | |
| various generic drugs | ||
Formulations
-
Tablets 5 mg, 25 mg, 50 mg, 100 mg, 200 mg
Reference
-
Синтез a)
-
US 4 602 017 (Wellcome; 22.7.1986; appl. 27.2.1984; prior. 15.9.1981, 29.5.1980; GB-prior. 1.6.1979).
-
US 4 847 249 (Wellcome; 11.7.1989; appl. 29.5.1987; GB-prior. 30.5.1986).
-
EP 21 121 (Wellcome; appl. 30.5.1980; GB-prior. 1.6.1979).
-
EP 59 987 (Wellcome; appl. 30.5.1980; GB-prior. 1.6.1979).
-
WO 2 008 019 798 (Lonza; 21.02.2008; USA-prior. 17.11.2006; EP-prior. 14.8.2006).
-
-
Синтез b)
-
US 6 683 182 (Helm AG; 27.1.2004; appl. 9.10.2003; PCT-prior. 4.7.2002; DE-prior. 17.7.2001).
-
EP 1 311 492 (Helm AG; appl. 4.7.2002; DE-prior. 17.7.2001).
-
Image may be NSFW.
Clik here to view.
http://www.google.com/patents/EP2128145A2?cl=en
Image may be NSFW.
Clik here to view.
Image may be NSFW.
Clik here to view.
EXAMPLES
-
[0047]The following examples are for illustrative purposes only and are not intended, nor should they be interpreted to, limit the scope of the invention.
General Experimental Conditions:I. HPLC Assay Method:
-
[0048]The chromatographic separation was carried out at room temperature (20-25° C) using a Lichrosphere RP-select B, 5 µm,4.0 x 250 mm I.D. column.
-
[0049]The mobile phase was prepared by mixing 320 mL of acetonitrile with 680 mL of buffer (pH = 5.6) prepared from 3.85 g of ammonium acetate dissolved in 1000 mL of water and by adjusting the pH to 5.6 with glacial acetic acid. The mobile phase was mixed and filtered through a 0.22 µm nylon filter under vacuum.
-
[0050]The chromatograph was equipped with a 306 nm detector, and the flow rate was 1.0 mL per minute. Test samples (20 µL) were prepared by dissolving the appropriate amount of sample in order to obtain 1 mg/mL of acetonitrile.
Example 1: Preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazineStep 1. Preparation of Lamotrigine
-
[0051]In a 800 L reactor, 38 kg of 2-(2,3-dichlorophenyl)-2-guanidinyliminoacetonitrile (0.148 kmoles) and 298 kg of isopropanol were combined. The mixture was then heated to reflux temperature (approximately 82° C) and maintained at 82 ± 3° C for 6 hours. Thereafter, the mixture was cooled to 20-25° C and stirred for 1 hour at this temperature. The suspension was then filtered and washed with 8 kg of isopropanol.
Step 2. Removal of Mechanical Impurities
-
[0052]The crude lamotrigine obtained in Step I and 335 kg of deionized water were combined in the 800 L reactor, and the temperature was adjusted to between 35 and 40° C. Methanesulfonic acid was then added to the mixture until the pH was between 1.5 and 2.0 while maintaining the temperature between 35 to 40° C. The resulting aqueous solution of lamotrigine methane sulfonate was then filtered, and the filter and reactor were washed with 4 kg of deionized water.
-
[0053]The solution of lamotrigine methanesulfonate was then added to the 800 L reactor, and the pH was adjusted to 6.5 to 7.5 by adding a 50% solution of sodium hydroxide. Next, the temperature was adjusted at 20 to 25° C, and the mixture was stirred at this temperature for 1 hour. Thereafter, the suspension was filtered and washed with 20 kg of deionized water followed by 8 kg of methanol, to obtain wet lamotrigine monohydrate.
Step 3. Conversion of Lamotrigine Hydrate to Anhydrous Lamotrigine
-
[0054]In the 800 L reactor, the wet lamotrigine hydrate obtained in Step 2 and 255 kg of filtered methanol were combined, and the mixture was heated to reflux temperature. The mixture was then cooled to 20-25° C and stirred at this temperature for 1 hour. Thereafter, the suspension was filtered and washed with 8 kg of methanol.
-
[0055]The wet product obtained was dried under vacuum for 16 hours at 85 ± 5° C and then was milled and sieved (500 µm to yield 29.11 kg (0.114 kmoles) of lamotrigine (Yield: 76.8%; Purity (HPLC analysis): 99.9%; Melting Point = 216° C).
Example 2: Preparation of Lamotrigine Monohydrate
-
[0056]Lamotrigine (46 g) and 460 mL of deionized water were combined, and the temperature of the mixture was adjusted at 3 5 to 40° C. Initially, the pH of the mixture was 4.11. Methanesulfonic acid was then added to the mixture until the pH was 1.4 while maintaining the temperature of the mixture at or below 30° C. A light, opaline solution was obtained following addition of the methanesulfonic acid. The obtained solution of lamotrigine methanesulfonate was then filtered and the filter was washed with 4.6 mL of deionized water.
-
[0057]The pH of the solution of lamotrigine methanesulfonate was next adjusted to 6.8-7.2 by adding a 50% solution of sodium hydroxide while maintaining the temperature at or below 30° C. The temperature was then adjusted to between 20° C and 25° C, and the mixture was stirred at this temperature for 1 hour. Thereafter, the suspension was filtered, and the obtained product was washed with deionized water and dried at 40° C to yield 49.23 g of lamotrigine monohydrate. Analysis: titration (perchloric acid): 99.23%; purity (HPLC analysis): 99%; Water (Karl Fischer) = 6.68%.
……………………………………
Example 6: Preparation of lamotrigine
The 6- (2,3, -dichlorophenyl) -5-chloro-3-thiomethyl-
1, 2,4-triazine prepared in Example 5 was dissolved in ethanol (100 ml) saturated with ammonia gas and heated in a sealed glass tube in an autoclave at 180°C/1930 kPa
(280 p.s.i.) for 72 hours.
The total contents of the tube was evaporated down to give a dark brown crude product. The crude product was recrystallised from methanol and identified as compound (I) , 3, 5-diamino-6- (2,3-dichlorophenyl) -1-2,4-triazine
(lamotrigine) by TLC (Rf = 0.20) . Melting point = 218°C.
http://www.google.com/patents/WO1996020935A1?cl=en
……………….
3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine of the Formula (I)
also known as lamotrigine, is the active ingredient of several pharmaceutical compositions used for the treatment of different diseases of the central nervous system (e.g. epilepsy).
The synthesis of substituted 3,5-diamino-1,2,4-triazine derivatives is known from the literature. In the following publications the general synthesis of substituted derivatives is described—Agr. Res. Serif. 3 188 (1966) and J. Med. Chem. 859 (1972)—according to which benzoyl cyanide is reacted with aminoguanidine in acidic medium and the so obtained adduct is cyclized under basic conditions. According to the process described in the European Patent No. 21121—analogously to the method described above—2,3-dichlorobenzoyl cyanide is reacted with the hydrogencarbonate salt of aminoguanidine in dimethyl sulfoxide as solvent, in the presence of 8 N nitric acid for 7 days. The obtained adduct is cyclized with methanolic potassium-hydroxide solution to the final product in 15% yield—calculated on the starting material. Basically similar process is described in the European Patent No. 142306. The disadvantages of the above processes are the extremely aggressive reaction medium, the long reaction time as well as the very low yield.
The European Patent No. 247842 describes a process in which 8 M solution of sulfuric acid is used instead of 8 N nitric acid in the condensation reaction, and the reaction time is 48 h. The cyclization reaction is carried out in n-propanol at reflux temperature. The yield is 41%. The disadvantages of this process are the low yield and the aggressive reaction medium.
Basically similar process is described in the U.S. Pat. No. 6,111,101, in which the condensation is carried out in a mixture of diluted sulfuric acid and acetonitrile for 60 h, then the cyclization is carried out with 1% aqueous potassium hydroxide solution. The yield is 44%. The crude product is purified by recrystallization from methanol with the help of clarifier. The disadvantages of the process are the aggressive medium, the low yield and the very long reaction time.
The modification of the above process is described in the European Patent No. 963980, in which the cyclization reaction is carried out in n-propanol at reflux temperature. The yield is 60%. The product is purified by recrystallization from n-propano 1. The disadvantages of this process are also the long reaction time and the aggressive reaction medium.
According to the International Patent Application No. WO96120934 an intermediate, which is prepared with great difficulty, is converted into lamotrigine by cyclizing in a photo-chemical reactor in 80% yield. The disadvantage of the process is that it can not be applied on industrial scale.
The International Patent Application No. WO96120935 describes a six-step synthesis, which is difficult to carry out and hardly realizable on industrial scale, as well as the yield of the final product is very low. The disadvantages of the process are the complicated synthesis, the applied hazardous reagents and the low yield.
http://www.google.com/patents/US7390899
EXAMPLE 23,5-diamino-6-(2,3-diehlorophenyl)-1,2,4-triazine
A suspension of 24.0 g of methanesulfonic acid and 21.0 g (0.079 mol) of aminoguanidine dimesylate is warmed to 65-70° C. in a 500 ml round bottom flask, equipped with a stirrer, a thermometer and a dropping funnel. The mixture becomes homogenous after 15 min, then a solution of 12.0 g (0.06 mol) of 2,3-dichlorobenzoyl cyanide in 10 ml of acetonitrile is added dropwise. The obtained mixture is stirred at 65-70° C. for 1 h. A mixture of 9 g (0.223 mol) of magnesium oxide and 60 ml of water is stirred for 5 min and the obtained suspension is added to the reaction mixture over a period of 10 min.
The temperature of the reaction mixture is raised to 70° C. and kept at this temperature for 3 h. The hot reaction mixture is filtered, 90 ml of water is added to the filtrate and concentrated. 60 ml of water is added to the residue, the suspension is stirred at 0-5° C., then filtered off. The product is washed with water and dried at 60-70° C. to yield 14.3 g (93.1%) of the crude title compound. Melting point: 212-216° C.
EXAMPLE 3Crystallization of 3,5-diamino-6-(2,3-diehlorophenyl)-1,2,4-triazine
10 g of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine is dissolved in 400 ml of acetone at reflux temperature, then 0.5 g of charcoal is added and the mixture is refluxed for 5 min. The clarifier is filtered off and the filtrate is cooled to 0-5° C. The precipitated crystals are filtered off and dried at 90° C. in vacuum to yield 7.0 g (70%) of the product. Melting point: 215-219° C.
………………………………………….
Lamotrigine 3,5-diamino-6-(2,3-dichlorophenyl)-l,2,4-triazine, is an antiepileptic drug, and its analogues were first disclosed in British Patent No. 759,014 (1956). Subsequently, Lamotrigine and its analogues were described in Canadian Patent Nos. 1,112,643 and 1,133,938, and in United States Patent No. 4,602,017. Processes for the preparation of Lamotrigine are also disclosed in international publications and patents WO 96/20934, WO 96/20935, WO 00/35888 and European Patent No. 963,980.
Lamotrigine 1
The process (as disclosed in Canadian Patent Nos. 1,112,643 and 1,133,938, United States Patent No. 4,602,017 and in British Patent No. 759,014) for the preparation of Lamotrigine involves reaction of 2,3-dichlorobenzoyl cyanide 2 and aminoguanidine bicarbonate in dimethylsulfoxide and 8N aqueous nitric acid (scheme 1). The above process uses drastic conditions (20 eq. 8N HNO3), excess reagents and requires 7 days for completion of the reaction. The overall yield of the process from 2,3-dichlorobenzoyl cyanide is 15.6%.
Scheme 1
2. MeOH, KOH, heat Lamotrigine 1 15.6% yield
The process reported in WO 00/35888 for this reaction uses H2S04 instead of 8N HNO3. However, it also suffers from lower yield (40%) and longer reaction time (2.5 days). The process also uses a large excess (-11 times) of sulfuric acid.
It is accordingly an object of the present invention to provide an improved process for the manufacture of lamotrigine which overcome the problems associated with poor efficiency described in the prior art. More broadly, it is an object of the present invention to provide novel processes for the production of 3,5-diamino-6-substituted-l,2,4-triazines.
SUMMARY OF THE INVENTION
In accordance with one aspect of the present invention, there is provided a process for the manufacture of an intermediate compound of formula IV
formula IV useful for manufacturing 3,5-diamino-6-substituted-l,2,4-triazines, wherein R is an optionally substituted C1-C4 alkyl or aryl group, which process comprises reacting a compound of formula II:
formula II
with aminoguanidine in the presence of an acid in an organic solvent under anhydrous conditions followed by treatment with a dehydrating reagent.
In accordance with another aspect of the present invention there is provided a process for the manufacture of 3,5-diamino-6-substituted-l,2,4-triazines of formula I:
formula I
comprising the steps of:
(a) reacting a compound of formula (II):
formula II
with aminoguanidine salts, or equivalent thereof, in the presence of an acid in an organic solvent under anhydrous conditions to form a cyanohydrin of formula III:
formula III
(b) dehydrating the cyanohydrin of formula III to form a compound of formula IV by treatment with a dehydrating reagent,
formula IV
and
(c) cyclization of the compound of formula IV into a 3,5-diamino-6- substituted-l,2,4-triazine of compound of formula I or into a hydrated form thereof.
Suitably the substituted Ci-Q alkyl group is methyl, ethyl, propyl or butyl and the substituted aryl group is preferably 2,3-dichlorophenyl.
The process of the present invention provides a high yielding and cost- effective process for the preparation of 3,5-diamino-6-substituted-l,2,4- triazines in general and Lamotrigine in particular. This result is obtained through the use of an additive, namely a dehydrating agent, such as thionyl chloride, POCI3 or PCI5, and by employing organic acid in combination with a polar organic solvent, which stabilizes the cyanohydrin of formula III. The cyanohydrin of formula III upon addition of a dehydrating agent affords the intermediate iminoguanidine of formula IV (scheme 2). The acid used in this process can be dry organosulfonic acids such as methanesulfonic acid or para-toluenesulfonic acid, either in combination with dry polar organic solvents, such as dimethylformamide (DMF), N-methyl-2- pyrrolidinone (NMP) or dimethylsulfoxide (DMSO), or combinations of a polar solvent with nonpolar solvents such as tetrahydrofuran (THF). The dehydrating reagents used in the process can be SOCl2, POCI3 or PCI5, oxalyl chloride, phosgene or equivalents thereof.
Scheme 2
dehydration ,
f
ormula II formula III
cyclisation
formula IV
The process, as shown in Scheme 2, involves the reaction of aryl cyanide, preferably 2,3-dichlorobenzoyl cyanide 2 (in which R = 2,3-dichlorophenyl), with an organic acid, for example para-toluenesulfonic acid or methanesulfonic acid, and dry organic solvents, for example DMSO, NMP or DMF, at suitable temperatures to form an intermediate of formula III. The reaction mixture is treated with dehydrates for example SOCl2, POCI3 or PCI5, oxalyl chloride, phosgene or equivalent thereof at a suitable temperature to form the iminoguanidine of formula IV. The iminoguanidine salt in the reaction mixture is cyclized upon basification and heating. The in inoguanidine salt can be basified and isolated by filtration. The isolated iminoguanidine can be cyclized to form Lamotrigine using a base (such as NaOH, NH3 or KOH) in a protic solvent (such as methanol, ethanol, isopropanol or water). Lamotrigine 1 can be isolated as the monohydrate when the cyclization of the intermediate is carried out using base and isopropanol/ water mixture or NMP/ water. The lamotrigine monohydrate is a new compound and is further characterized in having the following peaks in powder X-ray diffraction pattern at an angle of two theta (2Θ) is found to be: 10.34, 11.53, 12.46, 13.36, 13.86, 14.15, 14.94, 16.43, 16.65, 17.44, 17.97, 18.77, 18.91, 19.11, 19.52, 20.58, 22.11, 22.31, 23.09, 23.61, 24.18, 24.99, 25.52, 26.31, 26.83, 27.68, 28.53, 29.07, 29.24, 29.86, 30.09, 30.63, 31.01, 31.37, 31.78, 32.82, 33.25, 34.35, 34.96, 36.23, 36.92, 37.97, 38.60, 38.90. The positions of the peaks in powder X-ray diffraction pattern studies of anhydrous lamotrigine at an angle of two theta (2Θ) to be 9.80, 11.39, 12,46, 13.29, 13.86, 14.13, 15.62, 16.66, 17.44, 17.97, 19.54, 20.56, 22.30, 22.89, 23.61, 24.81, 25.50, 26.31, 26.74, 27.87, 28.42, 28.86, 29.38, 29.66, 30.95, 31.66, 32.59, 33.23, 33.61, 33.83, 34.21, 35.20, 36.27, 37.16, 37.90, 38.35, 38.92, 39.17, 39.45.
The overall yield of lamotrigine is high (molar yield: 80 – 85%). The above described process is very cost-effective, operationally simple and completed in a short time period (6 to 10 hours).
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is the powder X-ray diffraction pattern of lamotrigine monohydrate.
Figure 2 is a differential scanning calorimetry thermogram (DSC) of lamotrigine monohydrate.
Figure 3 is a Fourier transform infrared spectrum (FTIR) of lamotrigine monohydrate.
Figure 4 is the powder X-ray diffraction pattern of anhydrous lamotrigine. Figure 5 is a differential scanning calorimetry thermogram (DSC) of anhydrous lamotrigine.
Figure 6 is a Fourier transform infrared spectrum (FTIR) of anhydrous lamotrigine.
The following examples serve to illustrate embodiments of the present invention in a manner in which they can be practiced but, as such, should not be considered in a limiting sense.
EXAMPLES
Procedure I
To a round bottomed flask was added aminoguanidine hydrochloride (116.1 g, 1.05 mol) and dimethylformamide (900 mL). To this mixture was added methanesulfonic acid (130.4 g, 1.36 mol) followed by adding 2,3- dichlorobenzoylcyanide (150.0 g, 0.75 mol). The reaction mixture was stirred for 1 hour and then the dehydrating reagent, thionyl chloride, (45.2g, 0.38 mol) was added. The reaction mixture was stirred for another hour and then basified with KOH solution (4N). The precipitate was filtered and washed with water.
Yield: 401.3 g damp cake (KF = 39.2%).
Analytically pure sample of the intermediate is prepared as following:
20.0 g of the damp cake was suspended in 60 ml MeOH and stirred at room temperature for 3 hours. The solid was filtered and dried in vacuum at room temperature to give 5.4 g analytic pure iminoguanidine as a yellow solid.
m.p.: 179 ~ 180° C (corrected).
MS (m/z): 256.3 [M+] IR: 3491.8; 3457.1 (Amine N-H stretching); 2207.5 (CN stretching); 1681.9 (Imine C=N stretching); 1055.5 (Caryi-Cl stretching).
Η-NMR (300 MHz, DMSO-D6): 7.66 (ad, J = 7.9 Hz, 2H), 7.41 (dd, J = 7.9; 7.9 Hz, 1H), 6.70 (br s, NH2).
^C-NMR (75 MHz, DMSO-D6): 163.6, 135.3, 132.4, 130.0, 129.5, 129.0, 128.2, 114.4, 113.8.
Elemental analysis: C H N
Calculated: 42.21 2.76 27.35
Found: 42.10 2.49 27.69
Procedure II:
A round bottomed flask was charged with iminoguanidine (401.3 g from procedure I), isopropanol (1000.0 ml) and KOH (85%, 12.0 g, 0.18 mol). The reaction mixture was refluxed for 3 hours. Isopropanol was distilled and water (800 ml) was added. The reaction mixture was stirred for 3 hours, the solid was filtered and washed with water. The damp cake is dried under vacuum to yield 168.5 grams of lamotrigine monohydrate as crystalline solid (82% based on 2,3-dichlorobenzoyl cyanide).
Procedure III (without isolation of intermediate of formula IV):
To a round bottomed flask was added aminoguanidine hydrochloride (116.1 g, 1.05 mol) and dimethylformamide (900 ml). To this mixture was added methanesulfonic acid (130.4 g, 1.36 mol) followed by 2,3-dichlorobenzoyl cyanide (150.0 g, 0.75 mol). The reaction mixture was stirred for 1 hour and then dehydrating reagent thionyl chloride (45.2g, 0.38 mol) was added slowly. The reaction mixture was stirred for another hour and then basified with KOH solution (4 N). The Reaction mixture was heated under reflux (100 ~ 105° C) for 3 ~ 4 hours and cooled slowly to room temperature. The solid was filtered and washed with water. After drying, 160.7g of lamotrigine monohydrate as a crystalline solid (78% based on 2,3-dichlorobenzoyl cyanide) was obtained.
See also FIG. 1, 2, 3.
Karl Fischer (water content): 5.92 – 6.03%
DSC: 106.86, 216.65° C (onset).
MS (m/z): 256.3 [M+]
IR: 3496.9; 3450.3; 3338.5; 3211.0; 1658.7; 1524.0; 1328.8; 1027.1.
iH-NMR (300 MHz, DMSO-D6): 7.66 (ad, J = 7.9 Hz, 2H), 7.41 (dd, J = 7.9; 7.9 Hz, 1H), 6.70 (br s, NH2).
13C-NMR (75 MHz, DMSO-D6): 163.6, 135.3, 132.4, 130.0, 129.5, 129.0, 128.2, 114.4, 113.8.
Procedure IV (preparation of anhydrous lamotrigine from lamotrigine monohydrate):
150 g lamotrigine monohydrate (from procedure II or III) was recrystallized in 900 mL isopropanol giving 132 g (94%) of anhydrous lamotrigine as a crystalline solid.
See also FIG. 4, 5, 6.
m.p.: 216 – 217° C (corrected).
MS (m/z): 256.3 [M+]
Η-NMR (300 MHz, DMSO-D6): 7.69 (dd, J = 1.7; 7.9 Hz, 1H), 7.43 (dd, J = 7.9; 7.6 Hz, 1H), 7.35 (dd, J = 1.7; 7.6 Hz, 1H), 6.70 (br s, NH2), 6.44 (br s, NH2).
13C-NMR (75 MHz, DMSO-D6): 162.1, 154.1, 138.3, 136.8, 132.0, 131.6, 130.6, 128.5. Elemental analysis: C H N
Calculated: 42.21 2.76 27.35
Found: 42.10 2.58 27.46
http://www.google.com/patents/WO2003078407A1?cl=en
| Image may be NSFW. Clik here to view. |
|
| Image may be NSFW. Clik here to view.  |
|
| Systematic (IUPAC) name | |
|---|---|
| 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine | |
| Clinical data | |
| Trade names | Lamictal |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a695007 |
| Licence data | US FDA:link |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | 98% |
| Protein binding | 55% |
| Metabolism | Hepatic (mostly UGT1A4-mediated) |
| Half-life | 29 hours |
| Excretion | Urine (65%), faeces (2%) |
| Identifiers | |
| CAS number | 84057-84-1 Image may be NSFW. Clik here to view.  |
| ATC code | N03AX09 |
| PubChem | CID 3878 |
| IUPHAR ligand | 2622 |
| DrugBank | DB00555 |
| ChemSpider | 3741 Image may be NSFW. Clik here to view. |
| UNII | U3H27498KS Image may be NSFW. Clik here to view. |
| KEGG | D00354 Image may be NSFW. Clik here to view. |
| ChEBI | CHEBI:6367 Image may be NSFW. Clik here to view.  |
| ChEMBL | CHEMBL741 Image may be NSFW. Clik here to view. |
| Chemical data | |
| Formula | C9H7Cl2N5 |
| Mol. mass | 256.091 g/mol |
History
- December 1994 — Lamotrigine was approved for the treatment of partial seizures.[5]
- August 1998 — for use as adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients, new dosage form: chewable dispersible tablets.
- December 1998 — for use as monotherapy for treatment of partial seizures in adult patients when converting from a single enzyme-inducing anti-epileptic drug (EIAED).
- January 2003 — for use as adjunctive therapy for partial seizures in pediatric patients as young as two years of age.
- June 2003 — approved for maintenance treatment of Bipolar I disorder; the first such medication since lithium.[10]
- January 2004 — for use as monotherapy for treatment of partial seizures in adult patients when converting from the anti-epileptic drug valproate [including valproic acid (Depakene); sodium valproate (Epilim) and divalproex sodium (Depakote)].
Availability
Clik here to view.
Lamictal 200 mg tablets
GlaxoSmithKline’s trademarked brand of lamotrigine, Lamictal, is manufactured in scored tablets (25 mg, 50 mg, 100 mg, 150 mg and 200 mg) and chewable dispersible tablets (2 mg, 5 mg and 25 mg). Five-week sample kits are also available; these include titration [66]instructions and scored tablets (25 mg for patients taking valproate, 25 mg and 100 mg for patients not taking valproate). Lamotrigine is also available in un-scored tablet form. In 2005, Teva Pharmaceutical Industries Ltd. began selling generic lamotrigine in the United States, but only in 5 mg and 25 mg chewable dispersible tablets.[67] On 23 July 2008 Teva began offering the full line of generic lamotrigine in the US.[68]Lamotrigine is also available in generic form[69] in the United States, the United Kingdom, Canada and Australia. It should be noted that brand name Lamictal is not available in 200 mg tablets in Canada, at all registered pharmacies (while 25, 100, and 150 mg are all offered). Starter kits are also not available in Canada.
Lamotrigine is marketed as Lamotrine in Egypt, Lamitrin in Bangladesh [1], Lamictin in South Africa, למוג’ין (Lamogine)[70] in Israel, and 라믹탈 in South Korea and generally named as Lamitor.
Lamictal XR
In 2009 GlaxoSmithKline received FDA Approval for an extended-release version of lamotrigine branded Lamictal XR.[71] Lamictal XR tablets are a novel preparation of lamotrigine, delivered in a tablet with an enteric coating that GlaxoSmithKline has branded DiffCORE. The extended release formulation is analogous to the instant release version, such that treatment may begin without titration[66] or recalibration of the dosage.
References
- ^ Jump up to:a b Barbosa L, Berk M, Vorster M (April 2003). “A double-blind, randomised, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes”. J Clin Psychiatry 64 (4): 403–7. doi:10.4088/JCP.v64n0407. PMID 12716240.
- Jump up^ Rogawski MA, Löscher W (July 2004). “The neurobiology of antiepileptic drugs”. Nat Rev Neurosci 5 (7): 553–564. doi:10.1038/nrn1430. PMID 15208697.
- Jump up^ Lees G, Leach MJ (May 1993). “Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex”.Brain Research 612 (1–2): 190–9. doi:10.1016/0006-8993(93)91660-K.PMID 7687190.
- Jump up^ Werz MA (October 2008). “Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release”. Ther Clin Risk Manag 4 (5): 1035–46.doi:10.2147/TCRM.S3343. PMID 19209284.
- ^ Jump up to:a b anonymous (19 March 2004). “EFFICACY SUPPLEMENTS APPROVED IN CALENDAR YEAR 2003″. FDA/Center for Drug Evaluation and Research. Retrieved 2008-04-09.
- Jump up^ Kasper, D (2005). Fauci AS, Braunwald E, et al, ed. eds. Harrison’s Principles of Internal Medicine, 16th ed. McGraw-Hill. pp. 3–22. ISBN 9780071466332.
- Jump up^ Tierny, LM Jr (2006). McPhee SJ, Papadakis MA, ed. Current Medical Diagnosis and Treatment, 45th ed. McGraw-Hill. ISBN 0071454101.
- Jump up^ French JA, Kanner AM, Bautista J, et al. (April 2004). “Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society”. Neurology 62 (8): 1261–73. doi:10.1212/01.WNL.0000123695.22623.32. PMID 15111660.
- Jump up^ Pellock JM (November 1999). “Managing pediatric epilepsy syndromes with new antiepileptic drugs”. Pediatrics 104 (5 Pt 1): 1106–16. doi:10.1542/peds.104.5.1106.PMID 10545555.
- ^ Jump up to:a b GlaxoSmithKline, 2003
- ^ Jump up to:a b Ghaemi, S.N., Shirzadi, A.A., Filkowski, M. (2008). “Publication Bias and the Pharmaceutical Industry: The Case of Lamotrigine in Bipolar Disorder”. Medscape J Med10 (9): 211. PMC 2580079. PMID 19008973.
- Jump up^ Goldberg JF, Calabrese JR, Saville BR, Frye MA, Ketter TA, Suppes T, Post RM, Goodwin FK. (2009). “Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo”. Clinical Psychiatry 70(9): 1273–80. doi:10.4088/JCP.08m04381. PMID 19689918.
- Jump up^ Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM (2003). “Lamotrigine: a review of its use in bipolar disorder”. Drugs 63 (19): 2029–50. doi:10.2165/00003495-200363190-00009. PMID 12962521.
- Jump up^ Geddes JR (May 2011). “Treatment of bipolar disorder”. = Lancet 11 (9878): 1672–82.doi:10.1016/S0140-6736(13)60857-0. PMID 23663953.
- Jump up^ “Acute Treatment — Formula and Implementation of a Treatment Plan”. Practice Guideline for the Treatment of Patients With Bipolar Disorder Second Edition. American Psychiatric Association. Retrieved 15 August 2010.
- Jump up^ “Main page”. Practice Guideline for the Treatment of Patients With Bipolar Disorder Second Edition. American Psychiatric Association. Retrieved 15 August 2010.
- Jump up^ Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, Monaghan ET, Leadbetter RA (2008). “Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials”. Bipolar disorders 10 (2): 323–333. doi:10.1111/j.1399-5618.2007.00500.x. PMID 18271912.
- Jump up^ Calabrese JR, Geddes JR, Goodwin GM (2009). “Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials”. British Journal of Psychiatry 194 (1): 4–9.doi:10.1192/bjp.bp.107.048504. PMID 19118318.
- Jump up^ Reid, JG; Gitlin MJ; Altshuler LL (July 2013). “Lamotrigine in psychiatric disorders”. J Clin Psychiatry 74 (7): 675–84. doi:10.4088/JCP.12r08046. PMID 23945444.
- Jump up^ Backonja M (June 2004). “Neuromodulating drugs for the symptomatic treatment of neuropathic pain”. Curr Pain Headache Rep 8 (3): 212–6. doi:10.1007/s11916-004-0054-4. PMID 15115640.
- Jump up^ Jensen, T. S. (2002). “Anticonvulsants in neuropathic pain: Rationale and clinical evidence”. European Journal of Pain 6: 61–68. doi:10.1053/eujp.2001.0324.PMID 11888243.
- Jump up^ Pappagallo M (October 2003). “Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine”. Clin Ther 25 (10): 2506–38. doi:10.1016/S0149-2918(03)80314-4. PMID 14667954.
- Jump up^ Medford, N. (2005). “Understanding and treating depersonalisation disorder”. Advances in Psychiatric Treatment 11 (2): 92–100. doi:10.1192/apt.11.2.92.
- Jump up^ Hermle, L.; Simon, M.; Ruchsow, M.; Geppert, M. (2012). “Hallucinogen-persisting perception disorder”. Therapeutic Advances in Psychopharmacology 2 (5): 199–205.doi:10.1177/2045125312451270. PMC 3736944. PMID 23983976.
- Jump up^ Erfurth, A.; Walden, J. O. R.; Grunze, H. (1998). “Lamotrigine in the Treatment of Schizoaffective Disorder”. Neuropsychobiology 38 (3): 204–205. doi:10.1159/000026540.PMID 9778612.
- Jump up^ Lieb, K.; Völlm, B.; Rücker, G.; Timmer, A.; Stoffers, J. M. (2009). “Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials”. The British Journal of Psychiatry 196 (1): 4–12. doi:10.1192/bjp.bp.108.062984.PMID 20044651.
- Jump up^ Stein, D. J.; Zungu-Dirwayi, N.; Van Der Linden, G. J. H.; Seedat, S. (2000). “Pharmacotherapy for post traumatic stress disorder (PTSD)”. In Stein, Dan. “Cochrane Database of Systematic Reviews”. doi:10.1002/14651858.CD002795.
- Jump up^ Öncü, B; Er, O; Çolak, B; Nutt, DJ (Mar 2014). “Lamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case series.”. Journal of psychopharmacology (Oxford, England) 28 (3): 282–3. PMID 23784736.
- Jump up^ Hancock EC, Cross JH. (2013). “Treatment of Lennox-Gastaut syndrome.”. Cochrane Database of Systematic Reviews (2). doi:10.1002/14651858.CD003277.pub3.
- ^ Jump up to:a b c d e “Lamictal Prescribing Information” (PDF). GlaxoSmithKline. May 2007. Retrieved 2008-04-09.
- Jump up^ Serrani Azcurra, DJ (Jun 2012). “Lamotrigine rechallenge after a skin rash. A combined study of open cases and a meta-analysis.”. Revista de psiquiatria y salud mental 6 (4): 144–9. doi:10.1016/j.rpsm.2012.04.002. PMID 23084805.
- ^ Jump up to:a b c http://www.drugs.com/monograph/lamotrigine.html
- ^ Jump up to:a b c unknown, unknown. National Institute of Healthhttp://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7e3572d-56fe-4727-2bb4-013ccca22678#nlm34070-3. Retrieved 8 May 2014. Missing or empty
|title=(help) - Jump up^ Nicholson, R J; Kelly, K P; Grant, I S (25 February 1995). “Leucopenia associated with lamotrigine”. BMJ. Retrieved 16 June 2010.
- Jump up^ Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjectsDixon, Ruth; Job, S., Oliver, R., Tompson, D., Wright, J. G., Maltby, K., Lorch, U. and Taubel, J. (2008). (July 2008). “Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects”. Br J Clin Pharmacol 2008 66 (3): 396–404.doi:10.1111/j.1365-2125.2008.03250.x.
- Jump up^ Motomura, E; Tanii, H; Usami, A; Ohoyama, K; Nakagawa, M; Okada, M (March 2012). “Lamotrigine-Induced Neuroleptic Malignant Syndrome Under Risperidone Treatment: A Case Report”. The Journal of Neuropsychiatry and Clinical Neurosciences 24 (2): E38-E39.doi:10.1176/appi.neuropsych.11040093. PMID 22772697.
- Jump up^ Ishioka, M; Yasui-Furukori, N; Hashimoto, K; Sugawara, N (July–August 2013). “Neuroleptic malignant syndrome induced by lamotrigine.”. Clinical Neuropharmacology 36(4): 131–132. doi:10.1097/WNF.0b013e318294799a. PMID 23783003.
- ^ Jump up to:a b c d unknown, unknown. “Lamictal”. National Institute of Health. Retrieved 8 May 2014.
- Jump up^ Reimers A, A; Helde G; Brodtkorb E (September 2005). “Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations”. Epilepsia (Blackwell Science) 46(9): 1414–7. doi:10.1111/j.1528-1167.2005.10105.x. PMID 16146436.
- ^ Jump up to:a b Sidhu J, J; Job S; Singh S; Philipson R (February 2006). “The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects”. Br J Clin Pharmacol. 61 (2): 191–9.doi:10.1111/j.1365-2125.2005.02539.x. PMC 1885007. PMID 16433873.
- Jump up^ FDA: Safety Alerts: Lamotrigine
- Jump up^ Berwaerts, K; Sienaert P; De Fruyt J (2009). “Teratogenic effects of lamotrigine in women with bipolar disorder”. Tijdschr Psychiatr (in Dutch) 51 (10): 741–50.PMID 19821242.
- Jump up^ Prakash; Prabhu LV, Nasar MA et al. (October 2007). “Lamotrigine in pregnancy: safety profile and the risk of malformations”. Singapore Med J 48 (10): 880–3. PMID 17909669.
- Jump up^ McVearry, KM; Gaillard WD; VanMeter J; Meador KJ (December 2009). “A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy”. Epilepsy Behav 16 (4): 609–16.doi:10.1016/j.yebeh.2009.09.024. PMID 19892603.
- Jump up^ Hale, TW (2008). Medications and Mothers’ Milk (13th ed.). Hale Publishing. p. 532.ISBN 978-0-9815257-2-3.
- Jump up^ anonymous. “Lamictal, Warnings & Precautions”. RxList Inc. Retrieved 2008-04-09.
- Jump up^ “The mechanisms by which AEDs affect cognition and the measures to prevent the adverse effects in immature rats”.
- Jump up^ Glaxo Smith Klein Clinical Study Register, Study No. LAM40120: Lamotrigine (Lamictal®) Treatment in adults with Attention Deficit Hyperactivity Disorder (ADHD), A pilot study
- Jump up^ Oncü B, Er O, Colak B, Nutt DJ (2014). “Lamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case series.”. J Psychopharmacol 28 (3): 282–3.doi:10.1177/0269881113493365. PMID 23784736.
- Jump up^ Foldvary, N; Perry M, Lee J et al. (December 2001). “The effects of lamotrigine on sleep in patients with epilepsy”. Epilepsia 42 (12): 1569–73. doi:10.1046/j.1528-1157.2001.46100.x. PMID 11879368.
- Jump up^ Bonanni, E; Galli R, Gori S et al. (June 2001). “Neurophysiological evaluation of vigilance in epileptic patients on monotherapy with lamotrigine”. Clin Neurophysiol 112 (6): 1018–22. doi:10.1016/S1388-2457(01)00537-5. PMID 11377260.
- Jump up^ Placidi, F; Marciani MG, Diomedi M et al. (August 2000). “Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive functions in focal epilepsy”. Acta Neurol Scand 102 (2): 81–6. doi:10.1034/j.1600-0404.2000.102002081.x.PMID 10949523.
- Jump up^ Sadler, M (March 1999). “Lamotrigine associated with insomnia”. Epilepsia 40 (3): 322–5.doi:10.1111/j.1528-1157.1999.tb00712.x. PMID 10080513.
- Jump up^ http://www.ehealthme.com/ds/lamictal/myoclonic+jerks Retrieved August 19, 2010. Myoclonic Jerk in the use of Lamictal.
- Jump up^ Rogawski, M (2002). “Chapter 1: Principles of antiepileptic drug action”. In Levy RH, Mattson RH, Meldrum BS, Perucca E. Antiepileptic Drugs, Fifth Edition. Lippincott Williams & Wilkins. pp. 3–22. ISBN 9780781723213.
- Jump up^ Thomas, SP; Nandhra HS; Jayaraman A (April 2010). “Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD)”. J Ment Health 19 (2): 168–75. doi:10.3109/09638230903469269. PMID 20433324.
- Jump up^ Ketter, TA; Manji HK; Post RM (October 2003). “Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders”. J Clin Psychopharmacol 23 (5): 168–75.doi:10.1097/01.jcp.0000088915.02635.e8. PMID 14520126.
- Jump up^ Braga, MF; Aroniadou-Anderjaska V; Post RM; Li H (March 2002). “. Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders”.Neuropharmacology 42 (4): 522–9. doi:10.1016/s0028-3908(01)00198-8.PMID 11955522.
- Jump up^ Shiah, IS; Yatham LN; Gau YC; Baker GB (May 2003). “. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders”. Prog Neuropsychopharmacol Biol Psychiatry 27 (3): 419–23. doi:10.1016/S0278-5846(03)00028-9. PMID 12691776.
- Jump up^ Southam, E; Kirkby D; Higgins GA; Hagan RM (Sep 1998). “Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats”. Eur J Pharmacol 25 (358(1)): 19–24. PMID 9809864.
- ^ Jump up to:a b “LAMICTAL (lamotrigine) tablet”. Daily Med. U.S. National Library of Medicine. Retrieved 2013-12-26.
- Jump up^ Ramsay RE, Pellock JM, Garnett WR, et al. (1991). “Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy”. Epilepsy Res. 10 (2–3): 191–200.doi:10.1016/0920-1211(91)90012-5. PMID 1817959.
- Jump up^ Cohen, AF; Land GS; Breimer DD; Yuen WC; Winton C; Peck AW (Nov 1987). “Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans”. Clin Pharmacol Ther 42 (5): 535–41. PMID 3677542.
- Jump up^ Goa, KL; Ross SR; Chrisp P (Jul 1993). “A review of its pharmacological properties and clinical efficacy in epilepsy”. Drugs 46 (1): 152–76. doi:10.2165/00003495-199346010-00009. PMID 7691504.
- Jump up^ Anderson, GD (May 1998). “A mechanistic approach to antiepileptic drug interactions.”.Pharmacother 32 (5): 554–63. doi:10.1345/aph.17332. PMID 9606477.
- ^ Jump up to:a b In medicine, titration is the process of gradually adjusting the dose of a medication until optimal results are reached.
- Jump up^ anonymous (17 February 2005). “Press Release, Teva Announces Settlement Of Lamictal Litigation With Glaxosmithkline”. Teva Pharmaceutical Industries Ltd. Retrieved 2008-04-09.
- Jump up^ http://www.tevapharm.com/pr/2008/pr_779.asp
- Jump up^ anonymous (2 March 2005). “Treatment for epilepsy: generic lamotrigine”. Department of Health (UK). Retrieved 2008-04-09.
- Jump up^ anonymous (2007). “LAMOTRIGINE”. http://www.drug.co.il. Retrieved 2008-04-14.
- Jump up^ Waknine Y (2009). “FDA Approves Extended-Release Lamotrigine for Adjunctive Treatment of Epilepsy”. MedScape. Retrieved 2010-05-18.
External links
- FAQ: Psychiatric Uses of Lamotrigine (Lamictal), by Ivan K. Goldberg, MD. Includes many references from the medical literature.
- Center for Drug Evaluation and Research: Lamictal — documents related to the FDA approval process, including medical reviews and correspondence letters.
- Epilepsy South Africa: MEDICATION FOR EPILEPSY — an Epilepsy FAQ with a list of medicines for treatment thereof, includes lamotrigine with South African trade name Lamictin
- Adverse Reactions — Reported adverse reactions and side-effects.
- U.S. National Library of Medicine: Drug Information Portal — Lamotrigine
| Cited Patent | Filing date | Publication date | Applicant | Title | |
|---|---|---|---|---|---|
| EP0021121A1 | May 30, 1980 | Jan 7, 1981 | The Wellcome Foundation Limited | 1,2,4-Triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them | |
| EP0800520B1 | Dec 29, 1995 | Jun 19, 2002 | The Wellcome Foundation Limited | Process for the preparation of lamotrigine | |
| US4560687 | Mar 5, 1984 | Dec 24, 1985 | Baxter Martin G | Substituted aromatic compounds | |
| US4602017 | Feb 27, 1984 | Jul 22, 1986 | Sawyer David A | Substituted aromatic compounds | |
| US5912345 | Dec 29, 1995 | Jun 15, 1999 | Glaxo Wellcome Inc. | Process for the preparation of lamotrigine | |
| US5925755 | Dec 29, 1995 | Jul 20, 1999 | Glaxo Wellcome Inc. | Process for the preparation of lamotrigine | |
| US60834821 | Title not available | ||||
| WO1996020935A1 | Dec 29, 1995 | Jul 11, 1996 | Grahame Roy Lee | Process for the preparation of lamotrigine | |
| WO1997000681A1 * | Jun 20, 1996 | Jan 9, 1997 | Alison Green Floyd | Pharmaceutical composition containing lamotrigine | |
| WO2000035888A1 | Dec 7, 1999 | Jun 22, 2000 | Sharad Kumar Vyas | An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine | |
| WO2001049669A1 | Jan 3, 2000 | Jul 12, 2001 | Tarur Venkatasub Radhakrishnan | A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine | |
| WO2002068398A1 * | Feb 27, 2002 | Sep 6, 2002 | Judith Aronhime | New crystal forms of lamotrigine and processes for their preparations | |
| WO2003078407A1 * | Dec 18, 2002 | Sep 25, 2003 | Brantford Chem Inc | A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines | |
| WO2005003104A2 * | Jun 28, 2004 | Jan 13, 2005 | Jubilant Organosys Ltd | Crystalline forms of lamotrigine monohydrate and anhydrous lamotrigine and a process for their preparation | |
| WO2009061513A1 * | Nov 10, 2008 | May 14, 2009 | Miranda L Cheney | Crystalline forms of lamotrigine |
| Reference | ||
|---|---|---|
| 1 | * | KUBICKI, M. ET AL: “Hydrogen bonding patterns in 3,5-diamino-6-aryl triazines” JOURNAL OF MOLECULAR STRUCTURE , 570(1-3), 53-60 CODEN: JMOSB4; ISSN: 0022-2860, 2001, XP002545066 |
| 2 | ROBERT W. JANES ACTA CRYST. vol. C45, 1989, pages 129 – 132 | |
Filed under: GENERIC DRUG Tagged: LAMOTRIGINE Image may be NSFW.
Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
